Denali Advisors LLC purchased a new stake in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 28,777 shares of the pharmaceutical company's stock, valued at approximately $1,115,000.
Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Dodge & Cox lifted its holdings in shares of GSK by 0.5% in the fourth quarter. Dodge & Cox now owns 68,440,912 shares of the pharmaceutical company's stock valued at $2,314,672,000 after purchasing an additional 353,749 shares in the last quarter. FMR LLC lifted its holdings in shares of GSK by 82.1% in the fourth quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company's stock valued at $1,786,475,000 after purchasing an additional 23,814,104 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of GSK by 0.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,566,922 shares of the pharmaceutical company's stock valued at $255,914,000 after purchasing an additional 35,134 shares in the last quarter. Mondrian Investment Partners LTD lifted its holdings in GSK by 17.6% during the fourth quarter. Mondrian Investment Partners LTD now owns 5,838,384 shares of the pharmaceutical company's stock worth $205,920,000 after acquiring an additional 874,004 shares during the period. Finally, Equity Investment Corp lifted its holdings in GSK by 5.3% during the first quarter. Equity Investment Corp now owns 4,174,189 shares of the pharmaceutical company's stock worth $161,708,000 after acquiring an additional 211,608 shares during the period. Institutional investors and hedge funds own 15.74% of the company's stock.
GSK Price Performance
GSK stock traded up $0.68 during midday trading on Tuesday, hitting $36.88. 2,880,040 shares of the company's stock were exchanged, compared to its average volume of 5,092,951. GSK PLC Sponsored ADR has a 52-week low of $31.72 and a 52-week high of $44.67. The stock has a 50-day moving average price of $38.98 and a two-hundred day moving average price of $37.43. The company has a debt-to-equity ratio of 1.21, a quick ratio of 0.58 and a current ratio of 0.87. The company has a market cap of $75.50 billion, a P/E ratio of 19.02, a PEG ratio of 1.47 and a beta of 0.50.
GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.08 by $0.05. GSK had a return on equity of 48.82% and a net margin of 9.89%. The firm had revenue of $10.06 billion during the quarter, compared to analysts' expectations of $7.52 billion. During the same period in the prior year, the business earned $0.43 EPS. The company's revenue for the quarter was up 2.1% compared to the same quarter last year. On average, equities research analysts forecast that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.
GSK Increases Dividend
The firm also recently declared a quarterly dividend, which was paid on Thursday, July 10th. Shareholders of record on Friday, May 16th were given a dividend of $0.4216 per share. This is a positive change from GSK's previous quarterly dividend of $0.39. The ex-dividend date was Friday, May 16th. This represents a $1.69 dividend on an annualized basis and a yield of 4.57%. GSK's dividend payout ratio is presently 87.63%.
Analysts Set New Price Targets
A number of brokerages recently commented on GSK. BNP Paribas began coverage on GSK in a report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price target on the stock. Wall Street Zen downgraded GSK from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. Berenberg Bank reissued a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Finally, Hsbc Global Res raised GSK to a "strong sell" rating in a research report on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $37.38.
Check Out Our Latest Research Report on GSK
GSK Company Profile
(
Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Read More
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
